RCS - Amgen Inc. - Statement re Possible Offer

AmgenAnnouncement

02/12/2022 08:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221202:nRSB4073Ia&default-theme=true

RNS Number : 4073I  Amgen Inc.  02 December 2022

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE
OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A
VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION

 

 

December 2, 2022

 

 

Amgen Inc. ("Amgen")

Possible offer for Horizon Therapeutics plc ("Horizon")

Announcement for the purposes of Rule 2.12 of the Irish Takeover Panel Act
1997, Takeover Rules, 2022 (the "Irish Takeover Rules")

 

Further to the announcement made by Horizon under Rule 2.4 of the Irish
Takeover Rules on November 29, 2022, Amgen confirms for the purposes of Rule
2.12 of the Irish Takeover Rules that any offer by Amgen for Horizon is, or is
likely to be, solely in cash.

 

Accordingly, there are no disclosure requirements under Rule 8.3(a) of the
Irish Takeover Rules in relation to relevant securities of Amgen.

 

There can be no certainty that an offer will be made, or as to the terms on
which any offer might be made.

A further announcement will be made as appropriate.

 

In accordance with Rule 26.1 of the Irish Takeover Rules, a copy of this
announcement will be made available at www.amgen.com no later than 12 noon
(Irish time) on the business day following the date of this announcement. The
content of any website referred to in this announcement is not incorporated
into and does not form part of this announcement.

 

Enquiries:

 

Amgen

 

Jessica Akopyan (media)        +1 805 440 5721

Arvind Sood (investors)         +1 805 447 1060

 

Statement required by the Irish Takeover Rules

 

The directors of Amgen accept responsibility for the information contained in
this announcement. To the best of the knowledge and belief of the directors
(who have taken all reasonable care to ensure that such is the case), the
information contained in this announcement is in accordance with the facts and
does not omit anything likely to affect the import of such information.

 

General

 

The release, publication or distribution of this announcement in or into
certain jurisdictions may be restricted by the laws of those jurisdictions.
Accordingly, copies of this announcement are not being, and must not be,
released, published, mailed or otherwise forwarded, distributed or sent in,
into or from any restricted jurisdiction. Persons receiving this announcement
(including, without limitation, nominees, trustees and custodians) should
observe these restrictions. Failure to do so may constitute a violation of the
securities laws of any such jurisdiction. To the fullest extent permitted by
applicable law, Amgen disclaim any responsibility or liability for the
violations of any such restrictions by any person.

 

This announcement is not intended to, and does not, constitute or form part of
(i) an offer or invitation to purchase or otherwise acquire, subscribe for,
tender, exchange, sell or otherwise dispose of any securities; (ii) the
solicitation of an offer or invitation to purchase or otherwise acquire,
subscribe for, tender, exchange, sell or otherwise dispose of any securities;
or (iii) the solicitation of any vote or approval in any jurisdiction,
pursuant to this announcement or otherwise.

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAZZMGZVZNGZZG